Venturi Wealth Management LLC Reduces Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Venturi Wealth Management LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 38.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,689 shares of the medical research company's stock after selling 1,033 shares during the period. Venturi Wealth Management LLC's holdings in Thermo Fisher Scientific were worth $1,045,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. BDF Gestion purchased a new position in Thermo Fisher Scientific during the 2nd quarter worth $6,368,000. Nisa Investment Advisors LLC boosted its holdings in Thermo Fisher Scientific by 6.2% during the third quarter. Nisa Investment Advisors LLC now owns 140,708 shares of the medical research company's stock worth $87,093,000 after buying an additional 8,180 shares during the last quarter. Lord Abbett & CO. LLC boosted its stake in shares of Thermo Fisher Scientific by 1.9% during the 1st quarter. Lord Abbett & CO. LLC now owns 78,247 shares of the medical research company's stock worth $45,478,000 after acquiring an additional 1,480 shares during the period. Seven Eight Capital LP bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth $1,161,000. Finally, ORG Partners LLC grew its stake in Thermo Fisher Scientific by 216.6% in the second quarter. ORG Partners LLC now owns 1,640 shares of the medical research company's stock valued at $890,000 after acquiring an additional 1,122 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on TMO shares. Robert W. Baird lowered their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating for the company in a research note on Thursday, October 24th. Raymond James increased their price target on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an "outperform" rating in a research note on Thursday, July 25th. JPMorgan Chase & Co. lifted their price target on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an "overweight" rating in a research note on Friday, September 20th. Sanford C. Bernstein decreased their price objective on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a "market perform" rating for the company in a research report on Thursday, October 24th. Finally, Wells Fargo & Company dropped their price target on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an "overweight" rating for the company in a research note on Thursday, October 24th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus price target of $649.33.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 9,000 shares of the company's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the completion of the sale, the chief executive officer now owns 14,608 shares of the company's stock, valued at $8,076,178.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the transaction, the chief executive officer now directly owns 121,192 shares in the company, valued at $67,175,513.68. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 9,000 shares of the firm's stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $552.86, for a total value of $4,975,740.00. Following the sale, the chief executive officer now directly owns 14,608 shares of the company's stock, valued at $8,076,178.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 37,150 shares of company stock valued at $20,651,865. Insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Trading Down 1.1 %

Shares of NYSE:TMO traded down $6.17 during midday trading on Tuesday, hitting $540.75. The company had a trading volume of 1,722,782 shares, compared to its average volume of 1,462,758. The stock has a market cap of $206.84 billion, a price-to-earnings ratio of 34.29, a PEG ratio of 3.65 and a beta of 0.79. The firm has a fifty day simple moving average of $592.59 and a 200 day simple moving average of $583.56. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 12 month low of $439.11 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm's revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.69 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be issued a $0.39 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.78%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.